Toronto, Canada – TheNewswire - April 28, 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSX-V:VPT, OTC:VPTDF), is proud to announce that its strategic partner, Lishman Global Inc., has formally submitted Ventripoint’s VMS+™ 4.0 system to China’s National Medical Products Administration (NMPA), commonly referred to as the Chinese FDA, for regulatory approval.Importantly, Lishman Global has qualified for the NMPA’s “green channel” pathway, an expedited review process designed to accel ...